Mark J. O’Connor

This study shows that combining androgen receptor inhibitors with PARP inhibitors enhances DNA damage in prostate cancer models, independent of BRCA mutations, by increasing double-strand breaks and micronuclei formation.

The paper identifies a gap schedule for combining a PARP inhibitor and a tumor-targeted nanoparticle chemotherapy to enhance efficacy while reducing bone marrow toxicity.